Emergo Therapeutics
Durham, US · Founded 2016 · Delaware corporation · 4 known investors
Find your way into Emergo Therapeutics
23 people in our graph share verified history with the Emergo Therapeutics team — schools, employers, funds. One of them is your warm intro.
Briggs Morrisonunlockedknows Robin Hyde-DeRuyscher · together at The University of Connecticut Health Center (overlapped)
×2knows the team · via Humacyte
×7knows the team · via State University of New York at Oswego
×2knows the team · via The University of Connecticut Health Center
Emergo Therapeutics develops drugs designed to modulate inflammatory responses by reducing the production and secretion of inflammatory cytokines, targeting damaging symptoms across a range of diseases. Its pharmaceutical programs address acute and chronic conditions including flu/influenza-like illness and Long COVID, with clinical trials conducted in coordination with the FDA.
Founders & leadership
Emergo Therapeutics was founded in 2016 by Robin Hyde-DeRuyscher.
RH
Robin Hyde-DeRuyscherinCSO, President and FounderHe brings experience in biotechnology research, drug development, manufacturing, and regulatory affairs, with background in biologics production, team leadership, and process development across multiple sites.
MK
Moise KhayrallahinCEOMoise Khayrallah is CEO of Emergo Therapeutics, which develops immunomodulatory drugs targeting inflammatory cytokine production across acute and chronic conditions. He brings over 35 years of pharmaceutical industry experience across large-scale pharma, contract research organizations, and biotechnology companies.
MP
Margaret PowellNamed on SEC filing
RH
Robert HelmedagNamed on SEC filing
JE
John E. Bailey, Jr.Named on SEC filing
Investors · 4
Reported raises · per SEC filings
Form D private placements$16M disclosed across 3 rounds · 2018–2022
▶$500KraisedMay 2022 · 2 investors · PharmaceuticalsRule 506(b)
▶$500KraisedMay 2022 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Margaret PowellDirector
- Robert HelmedagDirector
- John E. Bailey, Jr.Director
- Moise KhayrallahExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $500K
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedOct 2020 · 77 investors · PharmaceuticalsRule 506(b)
▶$3.5MraisedOct 2020 · 77 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Margaret PowellDirector
- Robert HelmedagDirector
- Moise KhayrallahExecutive Officer, Director
- John E. Bailey, Jr.Director
- Offering amount
- $5M
- Amount sold
- $3.5M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$12MraisedSep 2019 · 110 investors · PharmaceuticalsRule 506(b)
▶$12MraisedSep 2019 · 110 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Margaret PowellDirector
- Robert HelmedagDirector
- John E. Bailey, Jr.Director
- Moise KhayrallahExecutive Officer, Director
- Robin Hyde-DeRuyscherExecutive Officer
- Offering amount
- $12M
- Amount sold
- $12M
- Minimum investment
- $10K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Apogee Therapeutics5 shared keywordsApogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
Protego5 shared keywordsProtego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones. Its work targets patients affected by protein misfolding disorders.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Synthego4 shared keywordsSynthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.
Companies competing with Emergo Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Emergo Therapeutics do?
- Emergo Therapeutics develops drugs designed to modulate inflammatory responses by reducing the production and secretion of inflammatory cytokines, targeting damaging symptoms across a range of diseases. Its pharmaceutical programs address acute and chronic conditions including flu/influenza-like illness and Long COVID, with clinical trials conducted in coordination with the FDA.
- Who founded Emergo Therapeutics?
- Emergo Therapeutics was founded by Robin Hyde-DeRuyscher in 2016.
- Who are Emergo Therapeutics's investors?
- Emergo Therapeutics's investors include Rex Health Ventures, Wolfpack Investor Network, Hatteras Venture Partners, VentureSouth.
- How much funding has Emergo Therapeutics raised?
- Emergo Therapeutics has disclosed $16M raised across 3 rounds.
- Where is Emergo Therapeutics headquartered?
- Emergo Therapeutics is headquartered in Durham, US.